IBDEI0HQ ; ; 20-FEB-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 20, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23929,1,8,0)
 ;;=8^Hemoglobin E-beta Thalassemia
 ;;^UTILITY(U,$J,358.3,23929,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,23930,0)
 ;;=282.49^^193^1639^38
 ;;^UTILITY(U,$J,358.3,23930,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23930,1,1,0)
 ;;=1^282.49
 ;;^UTILITY(U,$J,358.3,23930,1,8,0)
 ;;=8^Oth Thalassemia
 ;;^UTILITY(U,$J,358.3,23930,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,23931,0)
 ;;=282.5^^193^1639^45
 ;;^UTILITY(U,$J,358.3,23931,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23931,1,1,0)
 ;;=1^282.5
 ;;^UTILITY(U,$J,358.3,23931,1,8,0)
 ;;=8^Sickle-cell Trait
 ;;^UTILITY(U,$J,358.3,23931,2)
 ;;=^110419
 ;;^UTILITY(U,$J,358.3,23932,0)
 ;;=282.60^^193^1639^43
 ;;^UTILITY(U,$J,358.3,23932,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23932,1,1,0)
 ;;=1^282.60
 ;;^UTILITY(U,$J,358.3,23932,1,8,0)
 ;;=8^Sickle-cell Disease Unspec
 ;;^UTILITY(U,$J,358.3,23932,2)
 ;;=^330077
 ;;^UTILITY(U,$J,358.3,23933,0)
 ;;=282.62^^193^1639^16
 ;;^UTILITY(U,$J,358.3,23933,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23933,1,1,0)
 ;;=1^282.62
 ;;^UTILITY(U,$J,358.3,23933,1,8,0)
 ;;=8^Hb-SS Disease w/ Crisis
 ;;^UTILITY(U,$J,358.3,23933,2)
 ;;=^330079
 ;;^UTILITY(U,$J,358.3,23934,0)
 ;;=282.61^^193^1639^17
 ;;^UTILITY(U,$J,358.3,23934,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23934,1,1,0)
 ;;=1^282.61
 ;;^UTILITY(U,$J,358.3,23934,1,8,0)
 ;;=8^Hb-SS Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,23934,2)
 ;;=^330078
 ;;^UTILITY(U,$J,358.3,23935,0)
 ;;=282.63^^193^1639^47
 ;;^UTILITY(U,$J,358.3,23935,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23935,1,1,0)
 ;;=1^282.63
 ;;^UTILITY(U,$J,358.3,23935,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,23935,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,23936,0)
 ;;=282.64^^193^1639^46
 ;;^UTILITY(U,$J,358.3,23936,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23936,1,1,0)
 ;;=1^282.64
 ;;^UTILITY(U,$J,358.3,23936,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,23936,2)
 ;;=^329911
 ;;^UTILITY(U,$J,358.3,23937,0)
 ;;=282.68^^193^1639^34
 ;;^UTILITY(U,$J,358.3,23937,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23937,1,1,0)
 ;;=1^282.68
 ;;^UTILITY(U,$J,358.3,23937,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,23937,2)
 ;;=^329912
 ;;^UTILITY(U,$J,358.3,23938,0)
 ;;=282.69^^193^1639^33
 ;;^UTILITY(U,$J,358.3,23938,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23938,1,1,0)
 ;;=1^282.69
 ;;^UTILITY(U,$J,358.3,23938,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,23938,2)
 ;;=^330081
 ;;^UTILITY(U,$J,358.3,23939,0)
 ;;=282.7^^193^1639^30
 ;;^UTILITY(U,$J,358.3,23939,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23939,1,1,0)
 ;;=1^282.7
 ;;^UTILITY(U,$J,358.3,23939,1,8,0)
 ;;=8^Oth Hemoglobinopathies
 ;;^UTILITY(U,$J,358.3,23939,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,23940,0)
 ;;=282.8^^193^1639^36
 ;;^UTILITY(U,$J,358.3,23940,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23940,1,1,0)
 ;;=1^282.8
 ;;^UTILITY(U,$J,358.3,23940,1,8,0)
 ;;=8^Oth Spec Hereditary Hemolytic
 ;;^UTILITY(U,$J,358.3,23940,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,23941,0)
 ;;=283.10^^193^1639^27
 ;;^UTILITY(U,$J,358.3,23941,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23941,1,1,0)
 ;;=1^283.10
 ;;^UTILITY(U,$J,358.3,23941,1,8,0)
 ;;=8^Non-autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,23941,2)
 ;;=^294004
 ;;^UTILITY(U,$J,358.3,23942,0)
 ;;=283.11^^193^1639^21
 ;;^UTILITY(U,$J,358.3,23942,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23942,1,1,0)
 ;;=1^283.11
 ;;^UTILITY(U,$J,358.3,23942,1,8,0)
 ;;=8^Hemolytic-uremic Syndrome
 ;;^UTILITY(U,$J,358.3,23942,2)
 ;;=^293663
 ;;^UTILITY(U,$J,358.3,23943,0)
 ;;=285.0^^193^1639^48
 ;;^UTILITY(U,$J,358.3,23943,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23943,1,1,0)
 ;;=1^285.0
 ;;^UTILITY(U,$J,358.3,23943,1,8,0)
 ;;=8^Sideroblastic Anemia
 ;;^UTILITY(U,$J,358.3,23943,2)
 ;;=^7204
 ;;^UTILITY(U,$J,358.3,23944,0)
 ;;=285.3^^193^1639^9
 ;;^UTILITY(U,$J,358.3,23944,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23944,1,1,0)
 ;;=1^285.3
 ;;^UTILITY(U,$J,358.3,23944,1,8,0)
 ;;=8^Antineoplastic Chemo Ind Anemia
 ;;^UTILITY(U,$J,358.3,23944,2)
 ;;=^338232
 ;;^UTILITY(U,$J,358.3,23945,0)
 ;;=285.8^^193^1639^35
 ;;^UTILITY(U,$J,358.3,23945,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23945,1,1,0)
 ;;=1^285.8
 ;;^UTILITY(U,$J,358.3,23945,1,8,0)
 ;;=8^Oth Spec Anemia
 ;;^UTILITY(U,$J,358.3,23945,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,23946,0)
 ;;=283.2^^193^1639^20
 ;;^UTILITY(U,$J,358.3,23946,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23946,1,1,0)
 ;;=1^283.2
 ;;^UTILITY(U,$J,358.3,23946,1,8,0)
 ;;=8^Hemolytic d/t Hemolysis
 ;;^UTILITY(U,$J,358.3,23946,2)
 ;;=^55770
 ;;^UTILITY(U,$J,358.3,23947,0)
 ;;=286.9^^193^1640^11
 ;;^UTILITY(U,$J,358.3,23947,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23947,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,23947,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,23947,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,23948,0)
 ;;=446.6^^193^1640^28
 ;;^UTILITY(U,$J,358.3,23948,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23948,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,23948,1,8,0)
 ;;=8^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,23948,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,23949,0)
 ;;=451.9^^193^1640^27
 ;;^UTILITY(U,$J,358.3,23949,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23949,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,23949,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,23949,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,23950,0)
 ;;=287.5^^193^1640^25
 ;;^UTILITY(U,$J,358.3,23950,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23950,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,23950,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,23950,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,23951,0)
 ;;=287.1^^193^1640^23
 ;;^UTILITY(U,$J,358.3,23951,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23951,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,23951,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,23951,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,23952,0)
 ;;=287.30^^193^1640^22
 ;;^UTILITY(U,$J,358.3,23952,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23952,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,23952,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,23952,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,23953,0)
 ;;=238.71^^193^1640^26
 ;;^UTILITY(U,$J,358.3,23953,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23953,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,23953,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,23953,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,23954,0)
 ;;=286.52^^193^1640^2
 ;;^UTILITY(U,$J,358.3,23954,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23954,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,23954,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,23954,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,23955,0)
 ;;=286.53^^193^1640^5
 ;;^UTILITY(U,$J,358.3,23955,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23955,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,23955,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,23955,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,23956,0)
 ;;=286.59^^193^1640^16
 ;;^UTILITY(U,$J,358.3,23956,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23956,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,23956,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,23956,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,23957,0)
 ;;=286.0^^193^1640^9
 ;;^UTILITY(U,$J,358.3,23957,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23957,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,23957,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,23957,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,23958,0)
 ;;=286.1^^193^1640^7
 ;;^UTILITY(U,$J,358.3,23958,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23958,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,23958,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,23958,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,23959,0)
 ;;=286.2^^193^1640^10
 ;;^UTILITY(U,$J,358.3,23959,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23959,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,23959,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,23959,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,23960,0)
 ;;=286.3^^193^1640^8
 ;;^UTILITY(U,$J,358.3,23960,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23960,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,23960,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,23960,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,23961,0)
 ;;=286.4^^193^1640^30
 ;;^UTILITY(U,$J,358.3,23961,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23961,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,23961,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,23961,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,23962,0)
 ;;=286.52^^193^1640^3
 ;;^UTILITY(U,$J,358.3,23962,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23962,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,23962,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,23962,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,23963,0)
 ;;=286.53^^193^1640^6
 ;;^UTILITY(U,$J,358.3,23963,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23963,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,23963,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,23963,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,23964,0)
 ;;=286.59^^193^1640^17
 ;;^UTILITY(U,$J,358.3,23964,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23964,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,23964,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,23964,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,23965,0)
 ;;=286.6^^193^1640^13
 ;;^UTILITY(U,$J,358.3,23965,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,23965,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,23965,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,23965,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,23966,0)
 ;;=286.7^^193^1640^1
